Intravitreal triamcinolone injection for chronic diffuse diabetic macular oedema
| Autor: | Remzi Avci, Berkant Kaderli, Fatma Düriye Akalp |
|---|---|
| Přispěvatelé: | Uludağ Üniversitesi/Tıp Fakültesi/Göz Hastalıkları Anabilim Dalı., Avcı, Remzi, Kaderli, Berkant, Akalp, Fatma Duriye |
| Rok vydání: | 2006 |
| Předmět: |
Male
Fluorescein angiography Injection Intraocular pressure Visual acuity Triamcinolone acetonide genetic structures Clinical examination Topical agent Triamcinolone Acetonide Endophthalmitis Diabetic retinopathy Diabetic macular edema Vitrectomy Treatment outcome Middle aged Drug safety Prospective cohort study medicine.diagnostic_test Membrane Clinical trial Female Safety medicine.symptom Human medicine.drug Adult medicine.medical_specialty Macular edema cystoid Clinical article Intravitreal triamcinolone injection Physical examination Follow-up studies Macular Edema Chronic disease Article Cataract Injections Intraocular hypertension Fluorescence angiography Ophthalmology Diffuse diabetic macular oedema medicine Humans Prospective study Glucocorticoids Vitreous body Aged business.industry Follow up medicine.disease eye diseases Topical medication Treatment Drug efficacy sense organs Aflibercept Ranibizumab Macular Degeneration business Removal Prospective studies |
| Zdroj: | Clinical and Experimental Ophthalmology. 34:27-32 |
| ISSN: | 1442-9071 1442-6404 |
| DOI: | 10.1111/j.1442-9071.2006.01103.x |
| Popis: | Purpose: To determine the efficacy and safety of intravitreal triamcinolone in chronic diffuse diabetic macular oedema. Methods: This prospective, interventional consecutive case series study consisted of 59 eyes (36 patients) with chronic diffuse diabetic macular oedema, which received an intravitreal injection of 4 mg triamcinolone acetonide. The results were evaluated by clinical examination and fluorescein angiography. Potential complications such as a rise in intraocular pressure, cataract progression and endophthalmitis were recorded. Results: All patients completed at least 6 months follow up. The mean visual acuity improved significantly from 0.17 ± 3.4 to a maximum of 0.30 ± 3.3 at the third postinjection month (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|